Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025
Altamira Therapeutics (OTCQB:CYTOF), focused on RNA delivery technology development beyond liver applications, has scheduled its First Half 2025 Financial Results and Business Update Call for August 29, 2025, at 8:00 am ET.
The conference call will feature prepared remarks from Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda. The event will be accessible via toll-free and international dial-in numbers, with a webcast option available. A replay will be accessible 30 minutes after the live event through September 12, 2025.
Altamira Therapeutics (OTCQB:CYTOF), impegnata nello sviluppo di tecnologie di veicolazione dell'RNA oltre le applicazioni epatiche, ha fissato la presentazione dei risultati finanziari del primo semestre 2025 e l'aggiornamento aziendale per il 29 agosto 2025 alle 8:00 ET.
La conferenza comprenderà interventi preparati del fondatore, presidente e CEO Thomas Meyer e della COO Covadonga Pañeda. L'evento sarà fruibile tramite numeri gratuiti e internazionali per la chiamata, con opzione webcast. Una replica sarà disponibile a partire da 30 minuti dopo la diretta fino al 12 settembre 2025.
Altamira Therapeutics (OTCQB:CYTOF), centrada en el desarrollo de tecnologías de entrega de ARN más allá de las aplicaciones hepáticas, ha programado su llamada de resultados financieros del primer semestre de 2025 y actualización empresarial para el 29 de agosto de 2025 a las 8:00 ET.
La conferencia incluirá intervenciones preparadas del fundador, presidente y CEO Thomas Meyer y de la COO Covadonga Pañeda. El evento podrá seguirse por números de acceso gratuitos y internacionales, con opción de webcast. Una repetición estará disponible desde 30 minutos después del evento en vivo hasta el 12 de septiembre de 2025.
Altamira Therapeutics (OTCQB:CYTOF)는 간 밖 응용을 포함한 RNA 전달 기술 개발에 주력하며, 2025년 상반기 재무 실적 및 사업 업데이트 컨퍼런스 콜을 2025년 8월 29일 오전 8시(동부시간)로 예정했습니다.
이번 컨퍼런스 콜에서는 창립자 겸 회장 겸 CEO Thomas Meyer와 COO Covadonga Pañeda의 준비 발언이 있을 예정입니다. 참석은 무료 및 국제 전화 접속 번호와 웹캐스트로 가능하며, 생방송 종료 30분 후부터 2025년 9월 12일까지 다시보기 서비스가 제공됩니다.
Altamira Therapeutics (OTCQB:CYTOF), axée sur le développement de technologies de délivrance d'ARN au‑delà des applications hépatiques, a programmé sa conférence sur les résultats financiers du premier semestre 2025 et sa mise à jour commerciale pour le 29 août 2025 à 8h00 ET.
La conférence comportera des interventions préparées de Thomas Meyer, fondateur, président et CEO, et de la COO Covadonga Pañeda. L'événement sera accessible via des numéros gratuits et internationaux, avec option de webdiffusion. Une rediffusion sera disponible à partir de 30 minutes après la diffusion en direct et jusqu'au 12 septembre 2025.
Altamira Therapeutics (OTCQB:CYTOF), das sich auf die Entwicklung von RNA-Liefertechnologien jenseits von Leberanwendungen konzentriert, hat seinen Geschäfts- und Finanzergebnisbericht für das erste Halbjahr 2025 sowie ein Unternehmensupdate für den 29. August 2025 um 8:00 Uhr ET angesetzt.
Auf der Konferenz werden vorbereitete Ausführungen von Gründer, Vorsitzender und CEO Thomas Meyer sowie der COO Covadonga Pañeda zu hören sein. Die Teilnahme ist über gebührenfreie und internationale Einwahlnummern sowie per Webcast möglich. Eine Aufzeichnung steht ab 30 Minuten nach der Live-Veranstaltung bis zum 12. September 2025 zur Verfügung.
- None.
- None.
HAMILTON, BERMUDA / ACCESS Newswire / August 26, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it will host its Half Year 2025 Financial Results and Business Update Call on Friday, August 29, 2025. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks.
Event: Altamira Therapeutics First Half 2025 Financial Results and Business Update Call
Date: Friday, August 29, 2025
Time: 8:00 am ET
Access:
Toll Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 427043
Webcast URL: https://www.webcaster4.com/Webcast/Page/2797/52765
Participants will be greeted by an operator and asked for the access code. If a caller does not have the code, they can reference the company name.
The call will be in listen-only mode.
A replay of the call will be available 30 minutes after the live event via the Investors section of the Altamira website at https://ir.altamiratherapeutics.com/.
Replay access:
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 52765
Expiration: Friday, September 12, 2025
About Altamira Therapeutics
Altamira Therapeutics (OTCQB:CYTOF) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a
Investor Contact
SOURCE: Altamira Therapeutics
View the original press release on ACCESS Newswire
FAQ
When is Altamira Therapeutics (CYTOF) hosting its H1 2025 earnings call?
How can investors access Altamira Therapeutics' (CYTOF) H1 2025 earnings call?
Who will be presenting at Altamira Therapeutics' (CYTOF) H1 2025 earnings call?
How long will the replay of Altamira Therapeutics' (CYTOF) H1 2025 earnings call be available?
